Prognostic value of pathogenic variants in Lafora Disease: systematic review and meta-analysis of patient-level data.
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
02 09 2023
02 09 2023
Historique:
received:
11
05
2023
accepted:
24
08
2023
medline:
4
9
2023
pubmed:
2
9
2023
entrez:
1
9
2023
Statut:
epublish
Résumé
Lafora disease (LD) is a fatal form of progressive myoclonic epilepsy caused by biallelic pathogenic variants in EPM2A or NHLRC1. With a few exceptions, the influence of genetic factors on disease progression has yet to be confirmed. We present a systematic review and meta-analysis of the known pathogenic variants to identify genotype-phenotype correlations. We collected all reported cases with genetically-confirmed LD containing data on disease history. Pathogenic variants were classified into missense (MS) and protein-truncating (PT). Three genotype classes were defined according to the combination of the variants: MS/MS, MS/PT, and PT/PT. Time-to-event analysis was performed to evaluate survival and loss of autonomy. 250 cases described in 70 articles were included. The mutated gene was NHLRC1 in 56% and EPM2A in 44% of cases. 114 pathogenic variants (67 EPM2A; 47 NHLRC1) were identified. The NHLRC1 genotype PT/PT was associated with shorter survival [HR 2.88; 95% CI 1.23-6.78] and a trend of higher probability of loss of autonomy [HR 2.03, 95% CI 0.75-5.56] at the multivariable Cox regression analysis. The population carrying the homozygous p.Asp146Asn variant of NHLRC1 genotype was confirmed to have a more favourable prognosis in terms of disease duration. This study demonstrates the existence of prognostic genetic factors in LD, namely the genotype defined according to the functional impact of the pathogenic variants. Although the reasons why NHLRC1 genotype PT/PT is associated with a poorer prognosis have yet to be fully elucidated, it may be speculated that malin plays a pivotal role in LD pathogenesis.
Sections du résumé
BACKGROUND
Lafora disease (LD) is a fatal form of progressive myoclonic epilepsy caused by biallelic pathogenic variants in EPM2A or NHLRC1. With a few exceptions, the influence of genetic factors on disease progression has yet to be confirmed. We present a systematic review and meta-analysis of the known pathogenic variants to identify genotype-phenotype correlations.
METHODS
We collected all reported cases with genetically-confirmed LD containing data on disease history. Pathogenic variants were classified into missense (MS) and protein-truncating (PT). Three genotype classes were defined according to the combination of the variants: MS/MS, MS/PT, and PT/PT. Time-to-event analysis was performed to evaluate survival and loss of autonomy.
RESULTS
250 cases described in 70 articles were included. The mutated gene was NHLRC1 in 56% and EPM2A in 44% of cases. 114 pathogenic variants (67 EPM2A; 47 NHLRC1) were identified. The NHLRC1 genotype PT/PT was associated with shorter survival [HR 2.88; 95% CI 1.23-6.78] and a trend of higher probability of loss of autonomy [HR 2.03, 95% CI 0.75-5.56] at the multivariable Cox regression analysis. The population carrying the homozygous p.Asp146Asn variant of NHLRC1 genotype was confirmed to have a more favourable prognosis in terms of disease duration.
CONCLUSIONS
This study demonstrates the existence of prognostic genetic factors in LD, namely the genotype defined according to the functional impact of the pathogenic variants. Although the reasons why NHLRC1 genotype PT/PT is associated with a poorer prognosis have yet to be fully elucidated, it may be speculated that malin plays a pivotal role in LD pathogenesis.
Identifiants
pubmed: 37658439
doi: 10.1186/s13023-023-02880-6
pii: 10.1186/s13023-023-02880-6
pmc: PMC10474773
doi:
Substances chimiques
NHLRC1 protein, human
EC 2.3.2.27
Ubiquitin-Protein Ligases
EC 2.3.2.27
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
263Informations de copyright
© 2023. Institut National de la Santé et de la Recherche Médicale (INSERM).
Références
J Biol Chem. 2018 May 11;293(19):7117-7125
pubmed: 29483193
Epilepsia. 2005 Oct;46(10):1695-7
pubmed: 16190947
BMJ. 2019 Jan 30;364:k4597
pubmed: 30700442
J Genet. 2018 Jul;97(3):611-624
pubmed: 30027899
Genes Dev. 2007 Oct 1;21(19):2399-409
pubmed: 17908927
Epilepsy Behav Case Rep. 2014 Jan 19;2:19-21
pubmed: 25667860
Cell Metab. 2019 Nov 5;30(5):903-916.e7
pubmed: 31523006
PLoS One. 2009 Jun 16;4(6):e5907
pubmed: 19529779
Hum Mol Genet. 2010 Dec 1;19(23):4726-34
pubmed: 20858601
IUBMB Life. 2008 Jan;60(1):79-81
pubmed: 18379996
Nat Neurosci. 2007 Nov;10(11):1407-13
pubmed: 17952067
EMBO Mol Med. 2017 Jul;9(7):906-917
pubmed: 28536304
Rev Neurol (Paris). 2022 Apr;178(4):315-325
pubmed: 34301405
Orphanet J Rare Dis. 2021 Aug 16;16(1):362
pubmed: 34399803
Eur J Neurol. 2022 Jun;29(6):1571-1586
pubmed: 35318776
PLoS One. 2013 Aug 05;8(8):e70151
pubmed: 23940540
Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8501-6
pubmed: 15930137
Hum Mol Genet. 2008 Mar 1;17(5):667-78
pubmed: 18029386
Dis Model Mech. 2023 Jan 1;16(1):
pubmed: 36511140
J Biol Chem. 2008 Feb 15;283(7):4069-76
pubmed: 18070875
J Neurol Sci. 2021 May 15;424:117409
pubmed: 33773408
Clin Case Rep. 2014 Apr;2(2):23-4
pubmed: 25356237
Epilepsia. 2014 Dec;55(12):e129-33
pubmed: 25270369